ADC Therapeutics at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
ADC Therapeutics exhibits at Booth 2529 at ASH 2026 in New Orleans. Its presence centres on non-Hodgkin lymphoma, supporting a symposium that answers community oncologists' questions about novel therapies. It also supports one on how biomarkers and drug mechanisms are reshaping management of diffuse large B-cell lymphoma.
| Organization | ASH 2026 Attendance |
|---|---|
ADC Therapeutics Lausanne, Switzerland | |
Antibody-drug conjugate developer that markets loncastuximab tesirine (Zynlonta) for relapsed or refractory diffuse large B-cell lymphoma. | Booth Exhibiting at Booth 2529 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. |
Find decision makers at ADC Therapeutics
Tell us what you sell and we’ll find the people at ADC Therapeutics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction